Uric Acid Reduction /Probiotics Premix/ZC-URA/ Clinical Probiotic Strains
Shelf life: 24 months
Storage conditions: Stored at -18℃ or lower
Functional Strains
Lacticaseibacillus paracasei X11
Lacticaseibacillus paracasei Lpc-C66
Bifidobacterium animalis subsp. lactis KV9
Bifidobacterium animalis subsp. lactis F1-7
Main Functions
Reduce purine intake
Alleviate gout symptoms
Improve hepatic and renal metabolism
1 Clinical Verification · 4 Patents for Invention · 17 Research Publications
Clinical Research Institution: Guangdong Second Provincial Hospital – a Tertiary Grade A Hospital
Clinical registration number: ChiCTR2500096029—A randomized, double-blind, placebo-controlled feeding study of compound Lactobacillus powder in patients with hyperuricemia (with or without gout).
√Within 8 weeks, uric acid decreased by nearly 20%, with a maximum reduction of 207 μmol/L
√Gout attacks reduced by 47%, and symptom duration shortened by 69%
√Reduced use of emergency gout medications
No. 1 in China · Collaboration with Grade III Class A Hospital · Clinically Evidenced Functional Probiotic Strain
Tertiary Hospital · Clinical Evidence-Based Medicine
A Randomized, Double-blind, Placebo-controlled Feeding Trial of Purineed ™ Premix Probiotics Powder in Patients with Hyperuricemia (With or Without Gout).
Research Institution: Guangdong Second Provincial General Hospital (a Grade III, Level A general hospital)
Total Sample Size: 50 patients with hyperuricemia (with or without gout) (mean serum uric acid level: 554 μmol/L)
Intervention Duration: 8 consecutive weeks of trial consumption
Primary Efficacy Indicators: Changes in serum uric acid levels, frequency of acute gout attacks, and use of emergency medication for acute gout attacks, etc.
Intervention Protocol: 2g, twice daily
Clinical Data 1: Changes observed over 8 weeks, with 72% of subjects showing a decrease in serum uric acid levels.
Trial Notes: The 8-week trial demonstrated that Purineed ™ exhibited a significant uric acid-lowering effect. 72% of the subjects experienced a reduction in uric acid levels, with the decrease generally around 20%.
Serum uric acid levels decreased by up to 207 μmol/L, significantly lower than individual baseline values.
Clinical Data 2: Gout attack frequency was reduced by 47%, and the attack duration was shortened by 69%.
Trial Notes: Compared to the control group, Purineed ™ significantly reduced the frequency of acute gout attacks by 47% and shortened the attack duration by approximately 69% (representing a 3.3-fold relative improvement in efficacy).
This indicates that Purineed ™ can effectively decrease the frequency of gout flare-ups and mitigate the severity of acute attacks, aiding in recovery.
Clinical Data 3: Reduced Medication Use – 100% of Users Required No Emergency Gout Medication
Trial Notes: After 8 weeks of trial consumption, the number of emergency medication uses in the test group was zero. 100% of the subjects in the test group did not require emergency medication due to acute gout attacks.
This indicates that Purineed ™ can effectively help individuals with hyperuricemia/gout avoid acute gout attacks, thereby reducing or even eliminating the need for emergency medication.
Clinical Report:
Purineed ™ Premix Probiotics powder has been shown to lower serum uric acid levels, significantly reduce reliance on emergency gout medication, decrease the frequency of gout attacks, and shorten their duration. The effects demonstrated potential sustainability, and the product exhibited a favorable overall safety profile.
*The above is a data excerpt. For detailed clinical reports, please consult Zhongchuang Yike (Shanghai) Biotechnology Co., Ltd. at 400-166-7858.